Click here to view the printer friendly version of this press release
"John Hazle of MD Anderson Cancer Center agrees. In fact, that's the reason, he says, MD Anderson signed on for a pre-clinical evaluation of Edward Flynn's magnetic nano-particle technology in August this year."
NEW YORK--"The race is on for a better mammogram" states the December 19th headline in Fortune Magazine's (online) story by Sierra Jiminez. The story then begins—and ends—with the breakthrough work of Edward R. Flynn, PhD, of Manhattan Scientifics Inc. (OTCBB: MHTX). Manhattan Scientifics is focused on the technology transfer and commercialization of disruptive technologies in the nano medicine space, including Dr. Flynn's early detection technology.
Dr. Flynn has spent 10 years perfecting an early detection technology that can spot cancerous tumor years earlier than a mammogram can, with no radiation and 100% specificity. Dr. Flynn's technology uses tiny, iron oxide nanoparticles, attached to known breast cancer antibodies—which can only bind to breast cancers. The bound nanoparticles create a magnetic signal that is detected by something called a SQUID machine; Dr. Flynn's patented technology enables the technician to see the cancer with as few as 100,000 cells. A mammogram typically sees a cancer when it is 100 million cells or larger.
The FORTUNE article points out that Dr. Flynn's technology's potential for early detection has attracted the attention of MD Anderson Cancer Center in Houston, noting that, "John Hazle of MD Anderson Cancer Center agrees. In fact, that's the reason, he says, MD Anderson signed on for a pre-clinical evaluation of Edward Flynn's magnetic nano-particle technology in August this year."
Manhattan Scientifics, Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.